Sonnet Biotherapeutics - Il-18 Clinical Trials Have Shown That, Although It Is Well Tolerated, Il-18 Has Poor Efficacy in Treatment of Cancers
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.